Background: The Problem Is Not Just the Mutation—It’s the Silencing of the Solution

Gene therapy for sickle cell disease has reached a transformative moment. Two hematopoietic stem-cell gene therapies are now FDA-approved—one introducing an antisickling HBB variant via lentiviral transfer, and another using CRISPR-Cas9 to disrupt the erythroid enhancer of BCL11A.^1,2 These represent meaningful progress, but they also raise a critical question: can we intervene more directly—and more precisely—at the level of γ-globin regulation?

The biology has long pointed us in that direction. Fetal hemoglobin (HbF), composed of α2γ2 chains, does not polymerize with HbS and acts as a potent endogenous anti-sickling agent. Individuals with hereditary persistence of fetal hemoglobin (HPFH) demonstrate dramatically attenuated disease, often bordering on clinical quiescence.³

The key regulatory elements underlying this phenotype are now well defined. Among them, the BCL11A binding site within the HBG1 and HBG2 promoters—approximately 110 base pairs upstream of transcription start sites—functions as a central silencing switch.^4,5 HPFH-associated mutations cluster precisely at these loci.

Prior strategies have largely targeted this axis indirectly, disrupting the BCL11A enhancer. Effective, yes—but still one step removed. Direct promoter editing offers a more proximal, mechanistically elegant solution: disable the switch itself, rather than modulating its regulator.

The RUBY trial provides the first clinical validation that this approach is not only feasible—but profoundly effective.⁶

The Study: Targeting the Lock Instead of the Key

Hanna and colleagues evaluated renizgamglogene autogedtemcel (reni-cel), an autologous hematopoietic stem-cell therapy engineered using AsCas12a to disrupt BCL11A binding sites within the HBG1 and HBG2 promoters.⁶

The use of AsCas12a is not incidental. Compared with Cas9, it offers distinct structural and kinetic advantages, enabling efficient and highly specific editing—an essential requirement for therapies dependent on durable stem-cell engraftment.⁷ Preclinical work demonstrated that promoter disruption drives robust HbF induction without impairing erythropoiesis.⁴

Eligible patients aged 12–50 years had severe sickle cell disease with recurrent vaso-occlusive events and no suitable matched donor. Following plerixafor mobilization and CD34+ cell collection, patients underwent busulfan-based myeloablation and received a single infusion of edited cells.

Although the trial was terminated early due to a strategic pivot toward in vivo editing, outcomes from 28 treated patients (median follow-up 9.5 months) provide a compelling dataset.⁶

Key Findings

Hemoglobin: From Chronic Deficit to Physiologic Normalization

Baseline hemoglobin levels reflected classic sickle cell physiology (mean 9.8 g/dL). By 6 months, levels rose to 13.8 g/dL—squarely within normal ranges—and remained stable without ongoing transfusion support.6

This is not incremental improvement. It is physiologic restoration.

HbF Induction: Early, Durable, and Pancellular

HbF levels reached a mean of 48.1% by month 4 and remained above 40% thereafter.6 Even more striking, F-cell distribution approached universality (≈99%), with sustained intracellular HbF concentrations >10 pg per cell.

This distinction is critical. It is not simply the quantity of HbF—it is its uniform distribution that prevents sickling. The phenotype achieved here closely mirrors HPFH.

Clinical Outcomes: Near-Elimination of Vaso-Occlusive Events

Patients experienced a mean of 4.6 severe vaso-occlusive events annually prior to enrollment. Post-treatment, 27 of 28 patients remained event-free, with follow-up extending beyond two years in some cases.⁶

The single exception occurred in the context of acute COVID-19 infection, underscoring that residual events may reflect external triggers or preexisting organ damage rather than insufficient editing.

Editing Efficiency: High, Specific, and Durable

On-target editing exceeded 75% at product release and remained robust in vivo, with sustained editing across hematopoietic compartments.6 Notably, no off-target effects were detected across analyzed samples.

Clinical and Translational Perspective

This study reframes how we think about curative therapy in sickle cell disease.

By targeting the γ-globin promoters directly, reni-cel operates at the most proximal regulatory node of HbF repression. The resulting HbF levels—exceeding 40% with near-complete pancellular distribution—surpass thresholds historically associated with disease modification.^3,8

This is not simply better than hydroxyurea—it is biologically distinct. Hydroxyurea typically achieves HbF levels of 15–20%. Here, we see a functional reprogramming of erythropoiesis.

Equally notable are the engraftment kinetics. Neutrophil and platelet recovery occurred at medians of 23 and 25 days, respectively, without evidence of prolonged cytopenias.⁶ This consistency supports scalability and clinical feasibility.

Importantly, improvements extended beyond hemoglobin metrics. Normalization of hemolysis markers suggests downstream benefits in endothelial function, pulmonary hypertension risk, and long-term organ preservation—outcomes that define the natural history of the disease but are difficult to capture in early trials.

Safety Considerations and Open Questions

The safety profile aligns with expectations for myeloablative autologous transplantation. Common grade ≥3 events—febrile neutropenia, stomatitis, mucosal inflammation—reflect conditioning toxicity rather than gene editing itself.⁶

Serious events attributed to reni-cel were rare and manageable.⁶

However, several questions remain:

• Durability: Median follow-up remains under 1 year for many patients
• Clonal dynamics: Long-term stability of edited stem-cell populations is unknown
• Access: Manufacturing complexity and infrastructure requirements remain major barriers¹⁰

These issues will ultimately determine whether this approach can scale beyond specialized centers.

What Comes Next: From Ex Vivo to In Vivo

The early termination of RUBY reflects a broader strategic shift: moving gene editing in vivo.

If successful, this transition could eliminate the need for myeloablation and ex vivo manipulation—dramatically expanding access. The RUBY trial provides essential proof-of-concept, validating the HBG1/HBG2 promoter as a therapeutic target.

Parallel work using base editing (risto-cel) targeting adjacent regulatory motifs further reinforces this convergence.¹¹

The field is no longer asking whether γ-globin reactivation works—it is now optimizing how best to deliver it.

Bottom Line

CRISPR-Cas12a–mediated disruption of BCL11A binding at the HBG1 and HBG2 promoters produces deep, durable HbF reactivation—normalizing hemoglobin and effectively eliminating vaso-occlusive events in the vast majority of patients.

The implication is profound: by precisely targeting the regulatory switch that silences fetal hemoglobin, we can functionally neutralize sickle cell disease.

The next frontier—bringing this strategy in vivo—may ultimately determine whether this becomes not just a cure, but a scalable one.

References

1. Kanter J, Thompson AA, Pierciey FJ Jr, et al. Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. 2023;98:11–22. doi:10.1002/ajh.26741
2. Frangoul H, Locatelli F, Sharma A, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390:1649–62. doi:10.1056/NEJMoa2309676
3. Steinberg MH. Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes. J Clin Med. 2020;9:3782. doi:10.3390/jcm9113782.
4. Métais JY, Doerfler PA, Mayuranathan T, et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 2019;3:3379–92. doi:10.1182/bloodadvances.2019000820
5. Janoudi T, Jagdale M, Wu M, et al. Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathies. Blood Adv. 2025;9:808–13. doi:10.1182/bloodadvances.2024014040
6. Hanna R, Frangoul H, Pineiro L, et al. CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat sickle cell disease. N Engl J Med. 2026;394:1281–91. doi:10.1056/NEJMoa2415550
7. Zhang L, Zuris JA, Viswanathan R, et al. AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines. Nat Commun. 2021;12:3908. doi:10.1038/s41467-021-24017-8
8. Steinberg MH, Chui DHK, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014;123:481–5. doi:10.1182/blood-2013-09-528067
9. Frangoul H, Hanna R, Walters MC, et al. CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat β-thalassemia. N Engl J Med. 2026;394:1292–1301. doi:10.1056/NEJMoa2501277
10. Sharma A, John TD. Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease. Lancet Haematol. 2024;11(8):e556–e559. doi:10.1016/S2352-3026(24)00175-3
11. Gupta AO, Sharma A, Frangoul H, et al. Base editing of HBG1 and HBG2 promoters for sickle cell disease. N Engl J Med. doi:10.1056/NEJMoa2504835.